Alterity Therapeutics Ltd (ATHE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alterity Therapeutics Ltd (ATHE) has a cash flow conversion efficiency ratio of -0.192x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.43 Million) by net assets ($54.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Alterity Therapeutics Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Alterity Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Alterity Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alterity Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alterity Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asiana IDT Inc
KO:267850
|
0.053x |
|
Velan Inc.
TO:VLN
|
-0.041x |
|
Hiscox Ltd
LSE:HSX
|
0.029x |
|
Fortune Parts Industry Public Company Limited
BK:FPI
|
0.028x |
|
2invest AG
XETRA:2INV
|
N/A |
|
Viatron Technologies Inc
KQ:141000
|
0.050x |
|
Happy City Holdings Limited Class A Ordinary shares
NASDAQ:HCHL
|
N/A |
|
GrowGeneration Corp
NASDAQ:GRWG
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Alterity Therapeutics Ltd (2002–2025)
The table below shows the annual cash flow conversion efficiency of Alterity Therapeutics Ltd from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see ATHE company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $42.40 Million | $-11.45 Million | -0.270x | +70.44% |
| 2024-06-30 | $13.80 Million | $-12.61 Million | -0.914x | -4.02% |
| 2023-06-30 | $22.81 Million | $-20.04 Million | -0.878x | -152.49% |
| 2022-06-30 | $35.47 Million | $-12.34 Million | -0.348x | +38.84% |
| 2021-06-30 | $30.47 Million | $-17.33 Million | -0.569x | +36.39% |
| 2020-06-30 | $10.55 Million | $-9.43 Million | -0.894x | -6.07% |
| 2019-06-30 | $16.55 Million | $-13.95 Million | -0.843x | -117.06% |
| 2018-06-30 | $16.08 Million | $-6.25 Million | -0.388x | -56.86% |
| 2017-06-30 | $23.69 Million | $-5.87 Million | -0.248x | -4.68% |
| 2016-06-30 | $31.37 Million | $-7.42 Million | -0.237x | +14.91% |
| 2015-06-30 | $39.11 Million | $-10.87 Million | -0.278x | +24.04% |
| 2014-06-30 | $37.69 Million | $-13.79 Million | -0.366x | +35.69% |
| 2013-06-30 | $13.97 Million | $-7.95 Million | -0.569x | +53.26% |
| 2012-06-30 | $5.62 Million | $-6.85 Million | -1.217x | -85.11% |
| 2011-06-30 | $6.93 Million | $-4.56 Million | -0.658x | +26.97% |
| 2010-06-30 | $5.23 Million | $-4.71 Million | -0.900x | +51.72% |
| 2009-06-30 | $3.75 Million | $-6.99 Million | -1.865x | -95.95% |
| 2008-06-30 | $9.89 Million | $-9.41 Million | -0.952x | +41.93% |
| 2007-06-30 | $5.61 Million | $-9.20 Million | -1.639x | -22.82% |
| 2006-06-30 | $8.73 Million | $-11.66 Million | -1.335x | -129.03% |
| 2005-06-30 | $19.51 Million | $-11.37 Million | -0.583x | -321.78% |
| 2004-06-30 | $38.47 Million | $-5.31 Million | -0.138x | +39.11% |
| 2003-06-30 | $15.78 Million | $-3.58 Million | -0.227x | -0.44% |
| 2002-06-30 | $16.68 Million | $-3.77 Million | -0.226x | -- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more